Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 160 results for fibrosis

  1. Pulmonary rehabilitation to improve outcomes in people with idiopathic pulmonary fibrosis:- Does pulmonary rehabilitation improve outcomes for people with idiopathic pulmonary fibrosis?

    with idiopathic pulmonary fibrosis:- Does pulmonary rehabilitation improve outcomes for people with idiopathic pulmonary...

  2. Glecaprevir–pibrentasvir for treating chronic hepatitis C (TA499)

    Evidence-based recommendations on glecaprevir–pibrentasvir (Maviret) for treating chronic hepatitis C in adults.

  3. Pharmacological therapy for advanced liver fibrosis in children and young people:- What is the clinical and cost effectiveness of pharmacological therapy in children and young people with advanced liver fibrosis?

    NG49/5 Question Pharmacological therapy for advanced liver fibrosis in children and young people:- What is the clinical and cost...

  4. Non-invasive tests for diagnosing NAFLD and advanced liver fibrosis in children and young people:- Which non-invasive tests most accurately diagnose NAFLD and advanced liver fibrosis in children and young people?

    advanced liver fibrosis in children and young people:- Which non-invasive tests most accurately diagnose NAFLD and advanced liver...

  5. Heart valve disease presenting in adults: investigation and management (NG208)

    This guideline covers investigation and management of heart valve disease presenting in adults. It aims to improve quality of life and survival for people with heart valve disease through timely diagnosis and appropriate intervention.

  6. Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)

    Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C in adults.

  7. Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis TS ID 11905

    Awaiting development [GID-TA11414] Expected publication date: TBC

  8. Pancreatitis (NG104)

    This guideline covers managing acute and chronic pancreatitis in children, young people and adults. It aims to improve quality of life by ensuring that people have the right treatment and follow-up, and get timely information and support after diagnosis.

  9. Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)

    Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for treating chronic hepatitis B in adults.

  10. Semaglutide for treating non-alcoholic steatohepatitis with significant liver fibrosis TS ID 11945

    Awaiting development [GID-TA11477] Expected publication date: TBC

  11. Lung texture analysis for measuring interstitial lung diseases (MIB272)

    NICE has developed a medtech innovation briefing (MIB) on lung texture analysis for measuring interstitial lung diseases .

  12. Molnupiravir for treating COVID-19 [ID6340]

    In development [GID-TA11409] Expected publication date: 29 January 2025

  13. Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115)

    This guideline covers diagnosing and managing chronic obstructive pulmonary disease or COPD (which includes emphysema and chronic bronchitis) in people aged 16 and older. It aims to help people with COPD to receive a diagnosis earlier so that they can benefit from treatments to reduce symptoms, improve quality of life and keep them healthy for longer.

  14. Developing a new pulmonary rehabilitation program tailored for interstitial lung disease with Newcastle upon Tyne Hospitals' Interstitial Lung Disease service

    ILD, with around 200 patients being diagnosed with idiopathic pulmonary fibrosis (IPF). This example won the 'NICE into Action' category...